Doctors Without Borders/Médecins Sans Frontières (MSF) frequently publishes updates, press releases, and other forms of communication about its work in more than 60 countries around the world. See the list below for the most recent updates or search by location, topic, or year.

November 07, 2016

In an attempt to break up the everyday routine for children undergoing tuberculosis treatment in Tajikistan, the MSF psychosocial team organizes celebration parties as part of MSF’s pediatric therapeutic play program.

October 26, 2016

NEW YORK/LIVERPOOL, OCTOBER 26, 2016 – At the annual Union World Conference on Lung Health, which started in Liverpool today, Doctors Without Borders/Médecins Sans Frontières (MSF) is sharing its experience of using the new tuberculosis drugs bedaquiline and delamanid to treat people with drug-resistant TB. MSF is also involved in two clinical trials to test new TB treatments, both of which will start enrolling patients soon.

October 25, 2016

South Africa has one of the highest burdens of tuberculosis (TB) and drug-resistant tuberculosis (DR-TB) in the world, with more than 20,000 people diagnosed with DR-TB in 2015. Yet the current DR-TB treatment regimen—which consists of a combination of multiple pills and daily injections—is only successful in about half of all people who receive it. New drugs such as delamanid offer the opportunity to provide more successful, tolerable treatment regimens to patients with few other options available.

October 12, 2016

“The World Health Organization’s annual look at the global state of tuberculosis this year makes for a shockingly bad report card: countries are failing to diagnose and treat millions of people with TB, which caused 1.8 million deaths last year. Governments need to get their heads out of the sand and realize that TB is not a disease consigned to the 1800s; we see and treat TB in our clinics every day, and it’s a deadly threat to all of us.

September 21, 2016

"Doctors Without Borders/Médecins Sans Frontières (MSF) welcomes the United Nations’s (UN) Political Declaration Antimicrobial Resistance, which recognizes the need to address – at the highest political levels – the complex issue of drug-resistant infections, which affect people in every part of the world. Now, governments have the responsibility to turn these words into action and fully implement nationally-tailored plans and global commitments to combat antimicrobial resistance (AMR).

September 16, 2016

"The sustainable development goals (SDGs) adopted with much fanfare just a year ago seek to end HIV, tuberculosis, and malaria by 2030. The replenishment of the Global Fund is the first concrete action taken by the international community since the adoption of these goals, and therefore a first test of the world leaders' will to make them a reality. Failure to reach the relatively modest Global Fund's replenishment target would be a clear message that the SDGs were but empty promises to the millions who, every year, continue to suffer and die from HIV, tuberculosis, and malaria."

May 12, 2016

The World Health Organization has just recommended that countries move toward shorter treatment regimens for some people with drug-resistant tuberculosis (DR-TB), including people co-infected with HIV, children, and people with simple MDR-TB who have not been treated before or and have no known resistance to any of the drugs in the regimen. This recommendation comes following results from a number of large observation cohort studies using the shortened regimen.

March 23, 2016

Since 2006, Doctors Without Borders/Médecins Sans Frontières (MSF) has been providing ambulatory medical and psychosocial care for people in Mumbai living with drug-resistant tuberculosis (DRTB), HIV, hepatitis C, or a combination of these diseases. The majority of the patients are HIV positive who require second or third line treatment. Narendra* is one of only two percent of drug-resistant TB patients in need that have access to these new drugs.

March 21, 2016

New York/Geneva, March 21, 2016—Two years after two new drugs to treat tuberculosis (TB)—the first in over 50 years—were conditionally approved for use, only two percent of the 150,000 people who need them most have been able to access them, according to Doctors Without Borders’ new edition of DR-TB Drugs Under the Microscope.

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

Pages